[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Pages 52095-52096]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13625]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Rapid Response Partnership Vehicle

    Notice is hereby given that, on April 12, 2024, pursuant to section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership 
Vehicle (``RRPV'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, A-line, Inc., Signal Hill, CA; ANP Technologies, 
Inc., Newark, DE; ARNAV Biotech Corp., Atlanta, GA; Action Medical 
Technologies LLC, Conshohocken, PA; AmerStem, Inc., Camarillo, CA; 
American Type Culture Collection, Manassas, VA; Aposense, Ltd., Petach 
Tikva, ISRAEL; Appili Therapeutics USA, Inc., Frederick, MD; Aptitude 
Medical Systems, Goleta, CA; Arranta Bio MA LLC, Watertown, MA; Asha 
Therapeutics LLC, Tampa, FL; BDO Public Sector LLC, Mclean, VA; BRCR 
Medical Center, Inc., Plantation, FL; Battelle Memorial Institute, 
Columbus, OH; BioInfoExperts LLC, Thibodaux, LA; Boost Biopharma, Inc., 
Amherst, MA; Bracane Company, Plano, TX; Capra Biosciences, Inc., 
Manassas, VA; Capricor Therapeutics, Inc., San Diego, CA; CellCarta 
Biosciences, Inc., Montreal, CANADA; Cerba Research USA, Inc., Lake 
Success, NY; Clarametyx Biosciences, Inc., Columbus, OH; Clarus 
Biologics, Inc., Chapel Hill, NC; Cue Health, Inc., San Diego, CA; 
D'Angelo Technologies LLC, Beavercreek, OH; DEKA Research & Development 
Corp., Manchester, NH; Datavant, Phoenix, AZ; Deutsches Zentrum 
f[uuml]r Infektionsforschung e.V., Braunschweig, GERMANY; Diagnostic 
Consulting Network LLC dba DCN Diagnostics, Carlsbad, CA; Diasorin 
Molecular, Cypress, CA; EMD Millipore dba MilliporeSigma, Burlington, 
MA; Ethris GmbH, Planegg, GERMANY; FONDAZIONE BIOTECNOPOLO DI SIENA, 
SIENA, ITALY; Flagship Labs, Cambridge, MA; Fred Hutchinson Cancer 
Center, Seattle, WA; Genentech, South San Francisco, CA; GiwoTech, 
Inc., Wilmington, DE; Global Action Alliance, Inc., Ashburn, VA; HDT 
Bio Corp., Seattle, WA; Hope Biosciences, Sugar Land, TX; IQVIA 
Government Solutions, Inc., Falls Church, VA; Icahn School of Medicine 
at Mount Sinai, New York, NY; InBios International, Seattle, WA; 
Injection Safety Industries LLC, Bowling Green, KY; Inovio 
Pharmaceuticals, Plymouth Meeting, PA; Integrated Biotherapeutics LLC 
dba IBT Bioservices, Rockville, MD; LTS Lohmann Therapie-Systeme AG, 
Andernach, GERMANY; Labcorp, Burlington, NC; Labcorp-Monogram 
Biosciences, South San Francisco, CA; Lyndra Therapeutics, Inc., 
Watertown, MA; Major, Inc., Los Angeles, CA; MalarVx, Inc., Seattle, 
WA; Mirimus, Inc., Brooklyn, NY; Nature's Toolbox, Inc., Rio Rancho, 
NM; New Horizon Biotech, Inc., Nazareth, PA; OncoC4, Inc., Rockville, 
MD; PIF Partners LLC, Englewood, NJ; PharmaJet, Inc., Golden, CO; 
Precision for Medicine, Inc., Frederick, MD; Revvity Health Sciences, 
Hopkinton, MA; Rocketvax, Ltd., Basel, SWITZERLAND; Selva Therapeutics, 
Inc., San Mateo, CA; Sentio BioSciences LLC, Maryland Heights, MO; 
Solaris Vaccines, Inc., Fort Collins, CO; Spring Discovery, Inc., San 
Carlos, CA; Technical Resources International, Inc., Bethesda, MD; The 
Emmes Company LLC, Rockville, MD; The Pandemic Institute (Legally 
hosted by the University of Liverpool), Liverpool, UNITED KINGDOM; 
Tonix Pharmaceutical Holdings, Chatham, NJ; Trawsfynydd Therapeutics, 
Inc., Rockville, MD; US Specialty Formulations LLC, Allentown, PA; 
Univercells S.A., Brussels, BELGIUM; VaxForm LLC, Bethlehem, PA; 
VisMederi Srl, Siena, ITALY; Vyriad, Inc., Rochester, MN; Walgreen Co., 
Deerfield, IL; Yourbio Health, Medford, MA; and iosBio, Ltd., Haywards 
Heath, UNITED KINGDOM, have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and RRPV intends to file additional 
written notifications disclosing all changes in membership.
    On January 5, 2024, RRPV filed its original notification pursuant 
to section 6(a) of the Act. The Department of Justice published a 
notice in the Federal

[[Page 52096]]

Register pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 
26928).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-13625 Filed 6-20-24; 8:45 am]
BILLING CODE P